Thrombosis

Company Initiates Phase I Human Testing for Orally Active Thrombin-Inhibitor

Published in Blood Weekly, February 10th, 2000

3-Dimensional Pharmaceuticals, Inc. (3DP) announced that it has begun Phase I human testing of its oral anticoagulant thrombin inhibitor, 3DP-4815.

3DP-4815 is being developed for the treatment of arterial and venous thrombosis. The Phase I trial will be a randomized, double-blind, placebo-controlled, rising dose study, involving up to 45 volunteers. The only oral anticoagulant currently marketed is warfarin (sold as Coumadin and various generic versions).

Thrombin is an enzyme that converts fibrinogen to fibrin, causing blood clotting. Excessive blood clotting, or thrombosis, is a significant factor in cardiovascular and related diseases. It is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-02-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry